Infinant Health
- Industry
- Biotechnology
- Founded Year
- 2011
- Headquarters
- Norwalk, Connecticut, USA
- Employee Count
- 9
Key People
- Mike Johnson - CEO
- Kaile Zagger - CEO
- Daniela Barile - Co-Founder
- Samara Freeman - Founder and Executive Director
- Mandy Kennedy - Chief Marketing Officer
- Arlene Fosmer - Chief Science Officer
- Patrick Cormier - VP, Finance & Controller
- Becca Duar - Associate Director, Product Marketing
- Rozana Zemlyansky - Sales Director
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with significant industry experience.
The leadership team includes individuals with over a decade of experience in relevant fields, enhancing the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: Addressing a critical need in infant health through microbiome development.
Infinant Health's products target the development of a healthy infant microbiome, crucial for immune system development and long-term health, addressing a pressing clinical need.
- Competition
-
Aspect: Somewhat crowded
Summary: Operating in a competitive market with several established players.
The infant probiotic market includes several companies offering similar products, which could impact Infinant Health's ability to capture significant market share.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing and commercializing probiotic strains involves moderate technical challenges.
While the development of probiotic strains like B. infantis EVC001 is complex, existing research and technologies provide a solid foundation, making the technical challenges moderate.
- Patent
-
Aspect: Strong
Summary: Possesses strong patent protection for its proprietary probiotic strains.
Infinant Health's proprietary strain, B. infantis EVC001, is protected by patents, providing a competitive edge and potential barriers to entry for competitors.
- Financing
-
Aspect: Well-funded
Summary: Secured substantial funding from reputable investors.
With $135 million raised from investors like Cargill and the Bill & Melinda Gates Foundation, Infinant Health is well-positioned financially to advance its initiatives.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Engaged in pivotal trials for its products.
Infinant Health's products are undergoing pivotal trials, a crucial step toward regulatory approval and market entry.
Opportunity Rollup
- Odds of Success
- 3.35
- Peak Market Share
- 4.3
- Segment CAGR
- 6.3%
- Market Segment
- Infant Probiotics
- Market Sub Segment
- Infant Gut Health
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.64 |
| 3 | 1.50 |
| 4 | 3.01 |
| 5 | 4.30 |
Key Takeaway
Infinant Health is well-positioned in the growing infant probiotic market, leveraging strong leadership and substantial funding to address critical health needs.